E
Ellen M. Ginzler
Researcher at SUNY Downstate Medical Center
Publications - 185
Citations - 26968
Ellen M. Ginzler is an academic researcher from SUNY Downstate Medical Center. The author has contributed to research in topics: Lupus erythematosus & Lupus nephritis. The author has an hindex of 63, co-authored 166 publications receiving 23359 citations. Previous affiliations of Ellen M. Ginzler include Johns Hopkins University School of Medicine & State University of New York System.
Papers
More filters
Journal ArticleDOI
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri,Ana Maria Orbai,Graciela S. Alarcón,Caroline Gordon,Joan T. Merrill,Paul R. Fortin,Ian N. Bruce,David A. Isenberg,Daniel J. Wallace,Ola Nived,Gunnar Sturfelt,Rosalind Ramsey-Goldman,Sang Cheol Bae,John G. Hanly,Jorge Sanchez-Guerrero,Ann E. Clarke,Cynthia Aranow,Susan Manzi,Murray B. Urowitz,Dafna D. Gladman,Kenneth C. Kalunian,Melissa Costner,Victoria P. Werth,Asad Zoma,Sasha Bernatsky,Guillermo Ruiz-Irastorza,Munther A. Khamashta,Søren Jacobsen,Jill P. Buyon,Peter J. Maddison,Mary Anne Dooley,Ronald F van Vollenhoven,Ellen M. Ginzler,Thomas Stoll,Christine A. Peschken,Joseph L. Jorizzo,Jeffrey P. Callen,S. Sam Lim,Barri J. Fessler,Murat Inanc,Diane L. Kamen,Anisur Rahman,Kristjan Steinsson,Andrew G. Franks,Lisa Sigler,Suhail Hameed,Hong Fang,Ngoc Minh Pham,Robin L. Brey,Michael H. Weisman,Gerald McGwin,Laurence S. Magder +51 more
TL;DR: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge regarding the immunology of SLE.
Journal ArticleDOI
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
Dafna D. Gladman,Ellen M. Ginzler,Charles H. Goldsmith,Paul R. Fortin,Matthew H. Liang,MB Urowitz,Paul A. Bacon,Stefano Bombardieri,John G. Hanly,Elaine M Hay,David A. Isenberg,Jones Jv,Kenneth C. Kalunian,Peter J. Maddison,Ola Nived,Michelle Petri,Martin Richter,Jorge Sanchez-Guerrero,M L Snaith,Gunnar Sturfelt,Deborah P M Symmons,Asad Zoma +21 more
TL;DR: This damage index for SLE records damage occurring in patients with SLE regardless of its cause and was demonstrated to have content, face, criterion, and discriminant validity.
Journal ArticleDOI
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Jan J. Weening,Vivette D. D'Agati,Melvin M. Schwartz,Surya V. Seshan,Charles E. Alpers,Gerald B. Appel,James E. Balow,Jan A. Bruijn,Terence Cook,Franco Ferrario,Agnes B. Fogo,Ellen M. Ginzler,Lee A. Hebert,Gary Hill,Prue Hill,J. Charles Jennette,Norella C T Kong,Philippe Lesavre,Michael D. Lockshin,Lai-Meng Looi,Hirofumi Makino,Luiz Antonio Ribeiro de Moura,Michio Nagata +22 more
TL;DR: The main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies.
Journal ArticleDOI
The classification of glomerulonephritis in systemic lupus erythematosus revisited
Jan J. Weening,Vivette D. D'Agati,Melvin M. Schwartz,Surya V. Seshan,Charles E. Alpers,Gerald B. Appel,James E. Balow,Jan A. Bruijn,Terence Cook,Franco Ferrario,Agnes B. Fogo,Ellen M. Ginzler,Lee A. Hebert,Gary Hill,Prue Hill,J. Charles Jennette,Norella C T Kong,Philippe Lesavre,Michael D. Lockshin,Lai-Meng Looi,Hirofumi Makino,Luiz Antonio Ribeiro de Moura,Michio Nagata +22 more
TL;DR: The main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies.
Journal ArticleDOI
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie,Michelle A. Petri,Omid Zamani,Ricard Cervera,Daniel J. Wallace,D. Tegzova,Jorge Sanchez-Guerrero,Andreas Schwarting,Joan T. Merrill,W. Winn Chatham,William Stohl,Ellen M. Ginzler,Douglas R. Hough,Z. John Zhong,William W. Freimuth,Ronald F van Vollenhoven +15 more
TL;DR: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.